TSFAE19d:	Subjects With Treatment-emergent Adverse Events by Female-specific FDA Medical Query (Broad) and Preferred Term; Female-specific Safety Analysis Set (Study jjcs - core)						
 	Active Study Agent 	Active Study Agent 	 	Risk Difference (%) (95% CI) 	Risk Difference (%) (95% CI) 	
OCMQ (Broad) 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	Xanomeline High Dose vs Placebo 	Xanomeline Low Dose vs Placebo 	
  Preferred Term, n (%) 	N=24 	N=39 	N=36 	  	  	
Abnormal Uterine Bleeding 	0 	1 (2.6%) 	1 (2.8%) 	-2.8 (-8.1, 2.6) 	-0.2 (-7.5, 7.1) 	
BLEEDING ANOVULATORY 	0 	1 (2.6%) 	1 (2.8%) 	-2.8 (-8.1, 2.6) 	-0.2 (-7.5, 7.1) 	
 	 	 	 	 	 	
Amenorrhea 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
 	 	 	 	 	 	
Bacterial Vaginosis 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
 	 	 	 	 	 	
Decreased Menstrual Bleeding 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
 	 	 	 	 	 	
Excessive Menstrual Bleeding 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	

Key: FMQ=FDA Medical Query 	
Key: FMQ=FDA Medical Query	
Key: FMQ=FDA Medical Query	
Key: FMQ=FDA Medical Query	
Key: FMQ=FDA Medical Query	
Key: FMQ=FDA Medical Query	
Note: Adverse events are coded using MedDRA version 26.0. 	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.